A major investment in an international research environment for life science is planned beside AstraZeneca in Mölndal, Gothenburg
Within a few years 7,000 people will be working in an area full of new businesses.
Geely’s plans for a European innovation centre at Lindholmen is one the largest establishments that Gothenburg has seen. The planned facility concerns 80,000 square metres and will have space for 3,500 people.
But now the Chinese carmaker’s plans have been outdone by Investors property company Vectura Fastigheter and the Gothenburg company Next Step, who together have secured a large plot by AstraZeneca’s research facility in Mölndal. The seller is AstraZeneca. The investment volume concerns around 3.5 billion Swedish krona (approximately 365 million euros).
The new plans cover 100,000 square metres, and together with AstraZeneca’s current 2,500 employees there will be space for 7,000 people, in an area that will become one of the most research intensive in Sweden.
Construction is planned to begin already in 2019 with the first companies moving in in 2021. The property will be fully developed within 10 years.
20 September 2018
Bioagora 2018 (Copenhagen)
19 September 2018
STZ OcuTox: Drug development know-how